Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexFemale
• Healthy volunteersNo

You may be able to join if

• Key Inclusion Criteria:
• Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian (regardless of the grade), primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded)
• Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ and bone marrow function, as described in the protocol
• Platinum-Resistant Ovarian Cancer, as described in the protocol
• Key Exclusion Criteria:
• Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study intervention(s)
• Documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study intervention(s)
• Another malignancy that is progressing or requires active treatment, as described in the protocol
• Untreated or active Central Nervous System (CNS) metastases, or carcinomatous meningitis, as described in the protocol
• Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency
• Moderate to large or ascites, as described in the protocol
• Bowel obstruction within last 3 months or current need for parenteral nutrition
• NOTE: Other protocol-defined inclusion/exclusion criteria apply

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

ubamatamab. A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen that is part of the T-cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T cells and MUC16-expressing tumor cells, which cross-links the T cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells. NCI Drug Dictionary

Treatments listed in the registry

• Ubamatamab (Drug): Administered per the protocol
• Bevacizumab (Drug): Administered per the protocol
• Cemiplimab (Drug): Administered per the protocol
• Fianlimab (Drug): Administered per the protocol
• PLD (Drug): Administered per the protocol
• Sarilumab (Drug): Administered per the protocol
• REGN10597 (Drug): Administered per the protocol

Randomized · Parallel · masking: None

Main goals

• Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment (Up to 3 years)

Other goals

• Cancer Antigen (CA) -125 response by Gynecologic Cancer Intergroup (GCIG) Criteria
• Complete Response (CR) rate by RECIST 1.1
• Disease Control Rate (DCR) by RECIST 1.1
• Duration of Response (DOR) by RECIST 1.1
• Progression-Free Survival (PFS) by RECIST 1.1
• Occurrence of Grade ≥ 2 Cytokine Release Syndrome (CRS) by Lee criteria
• Treatment-Emergent Adverse Events (TEAEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
• TEAEs by Lee criteria
• Concentration of ubamatamab in serum
• Concentration of fianlimab in serum
• Concentration of REGN10597 in serum
• Occurrence of Anti-Drug Antibodies (ADA) to ubamatamab
• Magnitude of ADA to ubamatamab
• Occurrence of ADA to fianlimab
• Magnitude of ADA to fianlimab
• Occurrence of ADA to cemiplimab
• Magnitude of ADA to cemiplimab
• Occurrence of ADA to REGN10597
• Magnitude of ADA to REGN10597

Planned enrollment: 297 (estimated).

• The University of Alabama at Birmingham, Birmingham, Alabama
• UC San Diego Health, La Jolla, California
• Cedars Sinai Medical Center, Los Angeles, California
• Mayo Clinic Jacksonville, Jacksonville, Florida
• University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
• Advent Health Cancer Institute, Orlando, Florida
• Tampa General Hospital Cancer Institute, Tampa, Florida
• University of Chicago, Chicago, Illinois
• The University of Kansas Cancer Center, Westwood, Kansas
• Norton Cancer Institute, St. Matthews Clinic, Louisville, Kentucky
• Massachusetts General Hospital, Boston, Massachusetts
• Karmanos Cancer Institute, Detroit, Michigan
• The Ohio State University Comprehensive Cancer Center, Hilliard, Ohio
• Providence Cancer Institute, Portland, Oregon
• University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, Pennsylvania
• West Penn Hospital of Allegheny Health Network, Pittsburgh, Pennsylvania
• Avera Cancer Institute Sioux Falls, Sioux Falls, South Dakota
• UT Southwestern Medical Center, Dallas, Texas
• Swedish Cancer Institute, Seattle, Washington
• University of Wisconsin, Madison, Wisconsin
• Medical College of Wisconsin, Milwaukee, Wisconsin

35 recruiting sites outside the US. Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT06787612
• NCI Drug Dictionary: C153129

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Sep 13, 2026. Public record; not medical advice.